As previously presented, gedatolisib + palbociclib + fulvestrant ('gedatolisib triplet”) and gedatolisib + fulvestrant ('gedatolisib doublet”) reduced the risk of disease progression or death versus ...
Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on ...
Roquefort Therapeutics is acquiring exclusive worldwide rights to a clinical-stage tumour inhibitor for £32m in an all-paper deal and raising £8.5 million.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results